Background: Urinary tract infections (UTIs) are amongst the most common infections encountered in clinical practice. The commonest bacterial agent involved in causation of UTIs is Escherichia coli. Cotrimoxazole is the recommended drug for the treatment of UTIs. Several studies have reported increasing trends in resistance against cotrimoxazole, fluoroquinolones and other antibiotics, including ciprofloxacin. The aims and objects of this study are isolation and identification of Escherichia coli from cases of urinary tract infections from inpatients and to find out its antibiotic resistance trends. Methods: This Study was conducted in the Department of Microbiology, RIMS, Imphal from October 2015 to September 2016. Urine specimens sent to the laboratory from inpatients (wards and ICU) were collected and further processed following standard operative procedures. Antibiotic susceptibility test was performed by Kirby Bauer’s disc diffusion method using Muller Hinton Agar as per Clinical and Laboratory Standards Institute (CLSI) guidelines and susceptibility pattern was noted. Results: Among 105 E.coli isolated, highest resistance was found for ceftazidime(91.4%), amoxicillin/clavulanic acid(87.6%) and ampicillin(85.7%) followed by ceftazidime/clavulanic acid (75.2%), ceftriaxone(75.2%), ciprofloxacin(73.3%), piperacillin/tazobactum(58%), and cotrimoxazole(46.6%). Few isolates (12.3%) were resistant to meropenem, amikacin (5.7%) gentamicin (23.8%) and oral nitrofurantoin (8.5%). 79(75.2%) isolates were found multidrug resistant (MDR) and 10 (9.5%) isolates were extensively drug resistant (XDR). Extended spectrum beta lactamase (ESBL) enzyme was detected in 34 (32.3%) E. coli isolates. Conclusion: Empirical therapy should be tailored to the surveillance data on the epidemiology and resistance patterns of common uropathogens to reduce treatment failures and the emergence of bacterial resistant strains
